Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

65.69EUR
7:04am EDT
Change (% chg)

€0.09 (+0.14%)
Prev Close
€65.60
Open
€65.20
Day's High
€65.71
Day's Low
€65.10
Volume
895,283
Avg. Vol
2,723,899
52-wk High
€92.97
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €82,650.16
Shares Outstanding(Mil.): 1,256.20
Dividend: 3.03
Yield (%): 4.62

Financials

  SASY.PA Industry Sector
P/E (TTM): 16.66 30.61 33.50
EPS (TTM): 3.94 -- --
ROI: 5.81 13.57 13.17
ROE: 8.62 15.25 14.98

WHO recommends testing before use of Sanofi's dengue vaccine

PARIS/CHICAGO The World Health Organization (WHO) said on Thursday Sanofi's vaccine against dengue should only be used after testing on individuals to assess whether they have ever been exposed to the infection.

Apr 19 2018

UPDATE 2-WHO recommends testing before use of Sanofi's dengue vaccine

* Sanofi confident in vaccine's safety (Changes headline, adds Sanofi comment)

Apr 19 2018

BRIEF-Sanofi confident in Dengvaxia's safety and potential

* SANOFI SAYS CONFIDENT IN DENGVAXIA’S SAFETY AND PROVEN POTENTIAL TO REDUCE DENGUE DISEASE BURDEN IN ENDEMIC COUNTRIES

Apr 19 2018

Sanofi's CFO Contamine to retire later this year

PARIS Sanofi's executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday.

Apr 17 2018

Sanofi's CFO Contamine to retire later this year

PARIS, April 17 Sanofi's executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday.

Apr 17 2018

Sanofi in talks to sell generics arm to Advent for $2.4 billion

PARIS French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. | Video

Apr 17 2018

Bank trio expected to lead financing on Zentiva sale

LONDON, April 17 (LPC) - Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s European generics drugs arm Zentiva, banking sources said.

Apr 17 2018

UPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 bln

* Healthcare sector has seen lots of M&A so far in 2018 (Adds detail)

Apr 17 2018

Sanofi in talks to sell generics arm Zentiva to Advent for 1.9 bln euros

PARIS, April 17 French healthcare group Sanofi has started exclusive talks with private equity firm Advent International over selling its Zentiva European generics drugs arm to Advent for 1.9 billion euros ($2.4 billion), the companies said.

Apr 17 2018

France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

PARIS French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros ($195 million), the companies said on Monday.

Apr 16 2018

Earnings vs. Estimates